Latest News

How Does Elysium Therapeutics' Hydrocodone Prodrug, O2P, Work?
How Does Elysium Therapeutics' Hydrocodone Prodrug, O2P, Work?

March 29th 2024

In the fourth and final part of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the key features of O2P as well as plans for further development of the hydrocodone prodrug.

Image credit: Dmitry | stock.adobe.com
How High-Quality, Curated Real-World Data from Clinical Data Registries Helps Improve Drug Trials

March 29th 2024

Image credit: klickit24 | stock.adobe.com
Potential First in Class Treatment for Cirrhosis Shows Positive Results in Phase II Trial

March 28th 2024

Veeva Heroes
CSL Behring and Takeda Discuss Advancing Clinical Development and the Future of Trials

March 28th 2024

What is Elysium Therapeutics' O2P?
What is Elysium Therapeutics' O2P?

March 28th 2024

Conference Coverage

View All
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials

February 19th 2024

SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials
SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials

February 14th 2024

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

February 13th 2024

SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden

February 13th 2024

Latest Videos
Podcasts
© Alex from the Rock - © Alex from the Rock - stock.adobe.com
Rinol Alaj, Jaclyn Patterson, Applied Clincial Trials Podcast

All News

© 2024 MJH Life Sciences

All rights reserved.